https://www.aigom.it/wp-content/uploads/2024/02/ARTICOLO-9febb.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-09 13:42:322024-02-09 13:43:30STUDIO KATHERINE: T-DM1 adiuvante vs trastuzumab per EBC HER2+ con malattia residua dopo terapia neoadiuvante (chemioterapia e anti-HER2). Analisi finale della IDFS e seconda interim analisi della OS.
https://www.aigom.it/wp-content/uploads/2024/02/ARTICOLO-5feb.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-05 09:02:192024-02-05 09:02:19PROPHYLACTIC RADIATION THERAPHY VERSUS STANDARD OF CARE FOR PATIENTS WITH HIGH-RISK ASYMPTOMATIC BONE METASTASIS: A MULTICENTER, RANDOMIZED PHASE II CLINICAL TRIAL.
https://www.aigom.it/wp-content/uploads/2024/01/CRITICAL-REVIEWS.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-01-26 10:33:532024-01-26 10:33:53PRACTICAL GUIDELINES FOR MOLECULAR TESTING OF CHOLANGIOCARCINOMA IN CLINICAL PRACTICE: ITALIAN EXPERTS’ POSITION PAPER.
https://www.aigom.it/wp-content/uploads/2024/01/ARTICOLO-1801.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-01-18 14:53:452024-01-18 14:53:45CARDIOVASCULAR DISEASE IN TESTICULAR CANCER SURVIVORS: IDENTIFICATION OF RISK FACTORS AND IMPACT ON QUALITY OF LIFE.
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-01-12 09:17:252024-04-01 17:43:03NUOVE INDICAZIONI RIMBORSATE DI TRASTUZUMAB DERUXTECAN: G.U. del 20 dicembre 2023
https://www.aigom.it/wp-content/uploads/2023/12/MONARCH-3.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-12-21 10:43:542023-12-21 10:44:14MONARCH 3: Risultati dell’analisi finale della sopravvivenza globale presentati al San Antonio Breast Cancer Symposium (SABCS) il 6 dicembre 2023.
https://www.aigom.it/wp-content/uploads/2023/12/MAINTAIN-TRIAL.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-12-04 10:20:012023-12-04 10:21:34Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
https://www.aigom.it/wp-content/uploads/2023/11/open-pts.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-11-28 09:43:402023-11-28 09:43:40Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
